The intersection of surgical precision and cutting-edge digital health is undergoing a radical transformation. As medical technology continues to evolve at an unprecedented pace, the American Society of Plastic Surgeons (ASPS) has once again solidified its commitment to innovation by announcing the five startups selected for the 2026 MedTech Innovator (MTI) Plastic Surgery specialty track.
These emerging companies—FeminAI, ImageAssist, GenesisTissue, Tissuelock, and GenAssist—represent the vanguard of medical advancement, chosen for their potential to disrupt the status quo, optimize patient outcomes, and redefine the boundaries of reconstructive and aesthetic medicine.
The Selection Process: A Gateway to Global Impact
The road to the 2026 MedTech Innovator program is notoriously rigorous. This year, the ASPS specialty track witnessed a record-breaking level of interest, with 135 early- to mid-stage startups submitting applications. These organizations, spanning the fields of medical devices, diagnostic tools, and digital health, were evaluated not merely on their technical ingenuity, but on their ability to solve real-world clinical challenges.
Following an exhaustive review process, 12 finalists were invited to San Francisco for a live-pitch judging session. There, in front of a panel of industry veterans and clinical experts, the companies demonstrated their solutions, defended their business models, and articulated their vision for the future of healthcare. The resulting five selections—FeminAI, ImageAssist, GenesisTissue, Tissuelock, and GenAssist—emerged as the cohort most capable of leveraging the MTI accelerator to move from prototype to commercial success.
A Strategic Partnership: Bridging the Gap Between Bench and Bedside
The collaboration between ASPS and MedTech Innovator, now in its fifth year, is built upon a simple but powerful premise: that innovation in plastic surgery is most effective when it is guided by the people who perform it.
"Plastic surgery has always been a specialty driven by innovation, and the Society’s unique partnership with MedTech Innovator allows us to help shape the next generation of technologies," said Babak Mehrara, MD, president of The Plastic Surgery Foundation. "By connecting entrepreneurs with the expertise of plastic surgeons, we’re helping ensure these solutions are developed with patients’ needs in mind while accelerating innovations that have the potential to strengthen patient care across the specialty."
This synergy serves to de-risk the development cycle. By embedding these startups within the ASPS network, the companies gain access to invaluable feedback from frontline surgeons, ensuring that the final products are not only technically sound but also practically applicable in the operating room.
The 2026 Cohort: Meet the Disruptors
The selected startups represent a diverse array of technological approaches to some of the most persistent challenges in the field:
- FeminAI: Focused on the application of artificial intelligence in gender-specific health and aesthetic outcomes, leveraging data to tailor surgical planning.
- ImageAssist: Utilizing advanced imaging software to provide surgeons with real-time visual guidance, minimizing error and improving procedural accuracy.
- GenesisTissue: A pioneer in the development of synthetic and bio-engineered tissue scaffolds designed to accelerate healing and reduce scarring.
- Tissuelock: Innovating in the realm of surgical closure and wound management, focusing on device-driven solutions to optimize postoperative outcomes.
- GenAssist: A digital health platform designed to streamline the patient experience, from pre-operative education to post-surgical recovery tracking.
These companies will now join a larger, prestigious cohort of 65 startups, all vying for a share of $800,000 in non-dilutive funding. The winners will be unveiled this fall at The MedTech Conference in Boston, an event recognized globally as the premier gathering for the medical technology industry.
A Chronology of Success: Five Years of Transformation
Since the inception of the ASPS-MedTech Innovator track in 2021, the program has served as a powerful engine for economic and clinical growth.
- 2021-2022: The inaugural years established the framework for the partnership, focusing on early-stage mentorship and clinical integration.
- 2023: The program saw a spike in investment activity, with participants successfully navigating the complexities of post-pandemic regulatory environments.
- 2024: The focus shifted toward digital health and AI, reflecting broader market trends.
- 2025: The program reached a milestone of 18 total participants, with cumulative funding raised by cohort members topping $120 million.
- 2026: The current cycle, which promises to build upon the successes of the past, including the two companies that have already achieved successful exits—a significant achievement for any startup accelerator.
Over the last five years, the ASPS-MTI pipeline has proven that when you combine the clinical expertise of plastic surgeons with the business acumen of MTI’s mentors, the probability of commercialization and FDA authorization increases dramatically. To date, the program’s alumni have secured over $337,000 in direct MTI prizes, a testament to the quality of the startups selected.
Supporting Data: Why MedTech Innovator Matters
To understand the scale of the impact this program has, one must look at the parent organization. Since its founding in 2013, MedTech Innovator has grown into the world’s largest accelerator of its kind.
The metrics of success are staggering:
- Global Reach: The program has supported more than 800 startups across the globe.
- Financial Impact: Participants have collectively secured over $11 billion in equity funding.
- Regulatory Milestone: Alumni have achieved more than 500 FDA approvals and authorizations, proving that the accelerator is a vital bridge to market.
- Network Strength: The program is bolstered by 35 corporate partners and a network of over 1,000 senior industry executives, investors, and stakeholders.
For the five companies selected for the 2026 ASPS track, this means more than just a badge of honor. It means access to individualized, high-level mentorship. Each startup is paired with senior industry executives who provide strategic guidance on everything from intellectual property strategy to go-to-market execution.
Looking Ahead: Plastic Surgery The Meeting
The journey for these five companies is far from over. In the coming months, they will participate in a structured curriculum of coaching and mentorship. A major highlight of this journey will occur in Houston, from October 15-18, at Plastic Surgery The Meeting.
At this flagship event, the five startups will take center stage, showcasing their technologies to thousands of plastic surgeons, industry leaders, and potential investors. This provides a unique platform for the entrepreneurs to engage directly with the end-users of their products. This direct interaction is the "secret sauce" of the ASPS-MTI partnership; it allows for a candid exchange of ideas that can pivot a product from "good" to "market-essential."
Implications: The Future of Patient Care
The implications of this accelerator program extend well beyond the companies involved. By fostering a culture of innovation, ASPS is helping to ensure that the field of plastic surgery remains at the forefront of medical technology.
Enhanced Patient Safety
Technologies like ImageAssist and Tissuelock are fundamentally designed to reduce human error and improve the quality of tissue repair. In the context of reconstructive surgery, where precision is paramount, these tools can significantly reduce complications, shorten hospital stays, and improve long-term patient satisfaction.
Democratizing Access
The integration of digital health platforms like GenAssist means that the high-touch care associated with top-tier plastic surgery can be scaled. By automating post-operative care and patient education, these companies are helping to make high-quality care more accessible and more efficient, reducing the burden on surgical staff while increasing patient adherence to recovery protocols.
Economic Vitality
By providing a clear, mentored pathway for startups, the ASPS-MTI program lowers the barrier to entry for innovators. This encourages more talent to enter the medical technology space, ensuring a steady stream of new solutions that benefit the entire healthcare ecosystem.
Conclusion
The selection of FeminAI, ImageAssist, GenesisTissue, Tissuelock, and GenAssist is not just a routine administrative step; it is a signal of where the industry is heading. As we look toward the 2026 MedTech Conference in Boston, these five companies carry the hopes and the expertise of the entire ASPS community.
Through the combination of rigorous mentorship, clinical validation, and the sheer scale of the MedTech Innovator network, these startups are well-positioned to turn their innovative concepts into life-changing medical realities. For the patients who will ultimately benefit from these advancements, the work being done today in these accelerators is the difference between standard care and a future defined by surgical excellence and technological precision.
As the program continues to mature, it serves as a beacon for what is possible when professional societies and entrepreneurial ecosystems align. The next generation of medical technology is no longer a distant possibility—it is being built, tested, and refined right now, under the careful guidance of the ASPS and MedTech Innovator.
About the Author
